Combinations Alliance
Q. Describe the trial and the anticipated patient benefit.
Q. Describe the trial and the anticipated patient benefit.
In March this year, the NCRI Clinical and Translational Radiotherapy Working Group (CTRad) and the ECMC Combinations Alliance organised a joint Radiotherapy (RT)-Immunotherapy Workshop. This workshop, led by Dr Richard Adams and Professor Tim Illidge, aimed to highlight the drug development requirements of the RT and immunotherapy communities and select key proposals to take forward in discussions with companies for future development and funding.
February 1st saw Cancer Research UK’s first Risk Based Monitoring (RBM) workshop for members of the ECMC network in collaboration with the CRUK Combinations Alliance group and the Centre for Drug Development (CRUK CDD).
